Introduction
Managing pain after a cesarean section is a complex clinical challenge. Patients typically experience two distinct types of pain: sharp, localized "stinging" at the surgical incision site and deep, visceral "dull" aching from uterine contractions as the organ shrinks back to its pre-pregnancy size. While patient-controlled epidural analgesia (PCEA) is considered the gold standard for managing incision pain, it often fails to adequately address uterine contraction pain. This visceral pain is frequently triggered by breastfeeding and oxytocin infusions, which stimulate the production of prostaglandins.
This multi-center, prospective, randomized, blinded trial investigated whether adding intravenous flurbiprofen axetil—a targeted nonsteroidal anti-inflammatory drug (NSAID)—to a standard PCEA regimen could provide more comprehensive relief and improve recovery outcomes.
Methods and Study Design
The researchers conducted a large-scale trial involving 1,000 obstetric patients across four medical centers. Patients were classified as ASA physical status I or II and scheduled for elective cesarean delivery.
Participants were randomized into two groups:
- Group EF (Experimental): Received standard PCEA (0.1% ropivacaine + morphine) plus 50mg of intravenous flurbiprofen axetil immediately after delivery and twice daily for 48 hours.
- Group E (Control): Received standard PCEA plus a saline placebo.
Flurbiprofen axetil was chosen for its unique delivery system—lipid microspheres—which allows the drug to concentrate in inflamed tissues, reducing vascular irritation and enhancing efficacy. By inhibiting COX-1 and COX-2 enzymes, the drug blocks the synthesis of prostaglandins, the primary biochemical drivers of uterine pain.
Key Results
Enhanced Pain Relief
The study found that the combination therapy provided superior analgesia across multiple metrics. From 12 to 48 hours post-surgery, patients in Group EF reported significantly lower Visual Analogue Scale (VAS) scores for both uterine contraction pain and incision pain compared to the control group ($P < 0.01$). Notably, the relief extended to incision pain during movement (sitting and walking), suggesting that the NSAID effectively addressed "breakthrough" pain that local anesthetics alone might miss.
Accelerated Recovery of Gastrointestinal Function
One of the most striking findings was the impact on gastrointestinal (GI) recovery. The time to first "exhaust" (passage of flatus), a standard proxy for the return of bowel function, was nearly 40% faster in the flurbiprofen group (15 ± 6 hours vs. 25 ± 12 hours in the control group). This improvement is likely due to better pain control allowing for earlier mobilization; walking and light activity naturally stimulate gut motility.
Patient Satisfaction and Safety
Patient satisfaction scores were significantly higher in Group EF (3.2 vs. 2.9 on a 4-point scale). Furthermore, the incidence of constipation was lower in the flurbiprofen group ($P = 0.03$), while other common side effects like nausea, vomiting, and itching remained similar between the two groups. This suggests that the multimodal approach does not increase the side-effect burden while providing better clinical outcomes.
Discussion and Conclusion
The results of this trial underscore the importance of a multimodal approach to post-cesarean analgesia. By targeting the biochemical source of uterine pain—prostaglandin production—flurbiprofen axetil fills a critical gap left by epidural analgesia.
The study demonstrates that the benefits of effective pain management extend beyond comfort. Faster GI recovery and higher satisfaction scores indicate a higher quality of overall recovery, which is vital for new mothers who need to care for their newborns. While the study used a fixed 50mg dose, future research could explore dose optimization and the long-term psychological benefits of improved acute pain management, such as reduced rates of postpartum depression.
In conclusion, the combination of intravenous flurbiprofen axetil with PCEA offers a more effective and satisfying analgesic strategy for patients undergoing cesarean section, facilitating a faster return to normal function.
Summary updated